Towards Healthcare
Chronic Obstructive Pulmonary Disease Market Soars $34.76 Bn by 2034

Chronic Obstructive Pulmonary Disease (COPD) Market Trends and Developments

Based on market forecasts, the chronic obstructive pulmonary disease sector will expand from USD 22.55 billion in 2024 to USD 34.76 billion by 2034, experiencing a CAGR of 4.42%. In 2023, North America led the COPD market, with chronic bronchitis and drug treatments taking the top spots. Hospitals and clinics were the key end users. Looking ahead, Asia Pacific and oxygen therapy are expected to see the fastest growth.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific 
      • China
      • Japan
      • India
      • South Korea
      • Rest of Asia-Pacific
    • Rest of the World

North America Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Global Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • North America Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • U.S.
    • Canada

Europe Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Europe Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe

Asia-Pacific Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others
  • Asia-Pacific Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Country Type (2021 – 2033)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific

Rest of the World Chronic Obstructive Pulmonary Disease Market Assessment

  • Overview
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
    • Emphysema
    • Chronic Bronchitis
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
    • Drugs 
      • Bronchodilator Monotherapy
      • Short-Acting Beta2-Agonists (SABAs)
      • Long-Acting Beta2-Agonists (LABAs)
      • Anti-Inflammatory Drugs
      • Oral And Inhaled Corticosteroids
      • Anti-Leukotrienes
    • Surgery 
      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy
  • Rest of the World Chronic Obstructive Pulmonary Disease Market Size Value (US$) and Volume (Billion Tons), by End User Type (2021 – 2033)
    • Hospitals & Clinics
    • Homecare Settings
    • Others

Company Profiles

  • Almirall
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Abbott Laboratories
  • Dr. Reddy’s Laboratories Ltd.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Pfizer Inc.
  • Astellas Pharma
  • Novartis AG
  • Merck & Co., Inc.

Conclusion & Recommendations

  • Insight Code: 5154
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: April 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Breathing becomes more difficult with COPD. At initially, the symptoms might be minor, starting with breathlessness and sporadic coughing. Breathing may become more challenging as the symptoms worsen and become more persistent.

There are several similarities between COPD and asthma, including symptoms such as breathing difficulties and airflow obstruction. However, COPD is a progressive, long-term condition. Allergens frequently trigger asthma attacks. Smoking is the major cause of COPD.

Healthcare practitioners will be using a collection of established clinical and biochemical indicators that predict therapy by 2030 to evaluate our patients.

ClinicalTrails.gov, World Health Organization, U.S. National Library of Medicine, Centers for Disease Control and Prevention, American Lung Association